QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.078451v1 313/2/510    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O'Connor, K. A. Articles by Childers, S. R. Search for Related Content PubMed PubMed Citation Articles by O'Connor, K. A. Articles by Childers, S. R.

NEUROPHARMACOLOGY

Time-Dependent Changes in Receptor/G-Protein Coupling in Rat Brain following Chronic Monoamine Transporter Blockade

Department of Physiology/Pharmacology, Center for the Neurobiological Investigation of Drug Abuse, Wake Forest University Health Sciences, Winston-Salem, North Carolina (K.A.O., L.J.P., S.R.C.); and Department of Chemistry, State University of New York at Buffalo, Buffalo, New York (H.M.L.D.)

The potent tropane analog, WF-23 [2-propanoyl-3-(2-naphthyl) tropane], blocks dopamine, serotonin, and norepinephrine transporters with high affinity in vitro and blocks transporters for at least 2 days following a single in vivo administration. Previous studies demonstrated desensitization of monoamine receptor-coupled G-proteins in brain following chronic treatment of rats with WF-23. The current study sought to determine the time course of this desensitization and the behavioral effects of receptor desensitization. Rats were treated with 1 mg/kg WF-23 and injected i.p. every 48 h for 1 to 21 days. Receptor activation of G-proteins was determined by guanosine 5'-O-(3-[³⁵S]thiotriphosphate) ([³⁵S]GTPS) binding in brain sections for monoamine receptors, as well as µ opioid receptors as a nonmonoamine receptor control. Chronic treatment with WF-23 produced significant reductions in D₂, 5-hydroxytryptamine 1A, and ₂-adrenergic receptor-stimulated [³⁵S]GTPS binding; however, the time course of desensitization varied with different receptors. There was no effect of WF-23 treatment on µ opioid-stimulated [³⁵S]GTPS binding at any time point. Consistent with previous studies, there was no effect of WF-23 treatment on D₂ receptor binding, as determined by [³H]spiperone autoradiography. Locomotor activity was significantly increased for up to 48 h following acute administration of WF-23, demonstrated by increased photocell beam interruptions. WF-23-induced increases in locomotor activity occurred following repeated administration, as above, for up to 7 days. Following 7 days of treatment, there was a significant decrease in WF-23-increased locomotor activity. This reduction occurred at the same time point as the decrease in D₂ receptor/G-protein coupling, suggesting a role of D₂ desensitization in producing tolerance to WF-23-mediated behavior.

Address correspondence to: Steven R. Childers, Department of Physiology and Pharmacology, Wake Forest University Health Sciences, Medical Center Blvd., Winston-Salem, NC 27157. E-mail: childers{at}wfubmc.edu

This article has been cited by other articles:

				V. Murthy, T. J. Martin, S. Kim, H. M. L. Davies, and S. R. Childers In Vivo Characterization of a Novel Phenylisothiocyanate Tropane Analog at Monoamine Transporters in Rat Brain J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 587 - 595. [Abstract] [Full Text] [PDF]